This is a Phase I, exploratory safety study of the 480 Biomedical Mometasone Furoate Sinus Drug Depot in adult subjects with chronic sinusitis.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Management of Chronic Sinusitis
The Queen Elizabeth Hospital
Adelaide, Australia
Royal Brisbane and Women's Hospital
Brisbane, Australia
Monash Medical Center
Melbourne, Australia
University of Auckland
Auckland, New Zealand
Product related serious adverse events from baseline visit to 4 weeks post procedure
Time frame: 4 weeks post procedure
Plasma Mometasone Furoate concentration level from pre-treatment to end of treatment
Time frame: Up to 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.